Monoclonal antibodies: What are the pharmacokinetic and pharmacodynamic considerations for drug development?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 2, 2012, Pages 141-160

  Deng, Rong ^a   Jin, Feng ^b   Prabhu, Saileta ^a   Iyer, Suhasini ^a  

^a GENENTECH INC   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

first in human; monoclonal antibody; pharmacodynamics; pharmacokinetics; scaling

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CANAKINUMAB; CATUMAXOMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; DENOSUMAB; ECULIZUMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; GOLIMUMAB; IBRITUMOMAB TIUXETAN; INFLIXIMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OFATUMUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TOCILIZUMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; USTEKINUMAB;

ADVANCED CANCER; ANKYLOSING SPONDYLITIS; ANTIBODY STRUCTURE; ANTIGEN BINDING; ASTHMA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG STABILITY; DRUG TARGETING; ENTERITIS; GLYCOSYLATION; HUMAN; IMMUNOGENICITY; LIPOPHILICITY; MOLECULAR SIZE; NONHODGKIN LYMPHOMA; NONHUMAN; PREDICTION; REVIEW; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; DRUG DISCOVERY; HUMANS;

EID: 84856120429     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.643868     Document Type: Review

References (138)

1. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004;93(11):2645-68 (Pubitemid 39506617)
2. Subramanian GM, Cronin PW, Poley G, et al. A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers. Clin Infect Dis 2005;41(1):12-20 (Pubitemid 40863738)
3. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84(5):548-58
4. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv 2007;4(4):427-40 (Pubitemid 47249140)
5. Ratner M. Roche plans for more convenient-to-use Herceptin and Rituxan. Nat Biotechnol 2010;28(4):298
6. Keizer RJ, Huitema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49(8):493-507
7. Baxter LT, Zhu H, Mackensen DG, Jain RK. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 1994;54(6):1517-28 (Pubitemid 24106416)
8. Berger MA, Masters GR, Singleton J, et al. Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine model of human ovarian cancer. Cancer Biother Radiopharm 2005;20(6):589-602 (Pubitemid 43099609)
9. Wurster U, Haas J. Passage of intravenous immunoglobulin and interaction with the CNS. J Neurol Neurosurg Psychiatry 1994;57(Suppl):21-5 (Pubitemid 24356100)
10. Kairemo KJ, Lappalainen AK, Kaapa E, et al. In vivo detection of intervertebral disk injury using a radiolabeled monoclonal antibody against keratan sulfate. J Nucl Med 2001;42(3):476-82
11. Danilov SM, Gavrilyuk VD, Franke FE, et al. Lung uptake of antibodies to endothelial antigens: key determinants of vascular immunotargeting. Am J Physiol Lung Cell Mol Physiol 2001;280(6):L1335-47
12. Coffey GP, Fox JA, Pippig S, et al. Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice. Drug Metab Dispos 2005;33(5):623-9 (Pubitemid 40593875)
13. Junghans RP. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res 1997;16(1):29-57
14. Dickinson BL, Badizadegan K, Wu Z, et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 1999;104(7):903-11 (Pubitemid 29536340)
15. Spiekermann GM, Finn PW, Ward ES, et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med 2002;196(3):303-10 (Pubitemid 34875660)
16. Yeung YA, Wu X, Reyes AE II, et al. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res 2010;70(8):3269-77
17. Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci 2008;29(2):57-61
18. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 2008;60(12):1421-34
19. Reff ME, Heard C. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit Rev Oncol Hematol 2001;40(1):25-35 (Pubitemid 32923068)
20. Scheidhauer K, Wolf I, Baumgartl HJ, et al. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2002;29(10):1276-82 (Pubitemid 44392206)
21. Verel I, Heider KH, Siegmund M, et al. Tumor targeting properties of monoclonal antibodies with different affinity for target antigen CD44V6 in nude mice bearing head-and-neck cancer xenografts. Int J Cancer 2002;99(3):396-402 (Pubitemid 34495853)
22. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990;31(7):1191-8 (Pubitemid 20213280)
23. Graff CP, Wittrup KD. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res 2003;63:1288-96 (Pubitemid 36348707)
24. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970;49:673-80
25. Ghetie V, Hubbard JG, Kim JK, et al. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 1996;26(3):690-6 (Pubitemid 26091401)
26. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci USA 1996;93(11):5512-16
27. Brambell F, Hemmings W, Morris I. A theoretical model of gamma-globulin catabolism. Nature 1964;203:1352-5
28. Roopenian DC, Christianson GJ, Sproule TJ, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol 2003;170(7):3528-33 (Pubitemid 36359219)
29. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006;281(33):23514-24 (Pubitemid 44274126)
30. Dall'Acqua WF, Woods RM, Ward ES, et al. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002;169(9):5171-80 (Pubitemid 35217187)
31. Hinton PR, Johlfs MG, Xiong JM, et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 2004;279(8):6213-16 (Pubitemid 38248752)
32. Hinton PR, Xiong JM, Johlfs MG, et al. An engineered human IgG1 antibody with longer serum half-life. J Immunol 2006;176(1):346-56 (Pubitemid 43023280)
33. Petkova SB, Akilesh S, Sproule TJ, et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 2006;18(12):1759-69 (Pubitemid 44884038)
34. Yeung YA, Leabman MK, Marvin JS, et al. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 2009;182(12):7663-71
35. Deng R, Loyet KM, Lien S, et al. Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 2010;38(4):600-5
36. Dartois C, Freyer G, Michallet M, et al. Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease. Clin Pharmacokinet 2007;46:417-32 (Pubitemid 46686467)
37. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 2001;13(12):1551-9 (Pubitemid 33133882)
38. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007;7(9):715-25 (Pubitemid 47327396)
39. Yang BB, Lum P, Chen A, et al. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin Pharmacokinet 2010;49:729-40
40. Vectibix- (panitumumab): US prescribing information. Amgen Inc. Thounsand Oaks, CA, USA, 2011. Available from: http://pi.amgen.com/ united-states/ vectibix/vectibix-pi.pdf [Last accessed 31 May 2011]
41. Zia-Amirhosseini P, Minthorn E, Benincosa LJ, et al. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys. J Pharmacol Exp Ther 1999;291(3):1060-7
42. den Broeder A, van de Putte L, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol 2002;29(11):2288-98 (Pubitemid 35266018)
43. Xolair ® (omalizumab): US prescribing information. Genentech Inc, South San Francisco, CA, USA & Novartis Pharmaceuticals Corp, East Hanover, NJ, USA,2006. Available from: http://www. gene.com/gene/products/information/ pdf/ xolair-prescribing.pdf [Last accessed 31 May 2011]
44. Koon HB, Severy P, Hagg DS, et al. Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing. Leuk Res 2006;30(2):190-203 (Pubitemid 41773340)
45. Erbitux® (cetuximab): US prescribing information. Bristol-Myers Squibb Co, Princeton, NJ,USA and Eli Lilly and Co, Indianapolis, IN, USA, 2011. Available from: http://packageinserts.bms.com/pi/ pi-erbitux.pdf [Last accessed 31 May 2011]
46. Meijer RT, Koopmans RP, ten Berge IJ, Schellekens PT. Pharmacokinetics of murine anti-human CD3 antibodies in man are determined by the disappearance of target antigen. J Pharmacol Exp Ther 2002;300(1):346-53 (Pubitemid 34028546)
47. Ng CM, Stefanich E, Anand BS, et al. Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 2006;23(1):95-103 (Pubitemid 43214665)
48. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9(9):995-1001 (Pubitemid 28496709)
49. Li J, Levi M, Charoin J, et al. Rituximab Exhibits A Long half-life based on a population pharmacokinetic analysis in Non-hodgkin's Lymphoma (NHL) Patients[ASH Annual Meeting]. Blood 2007;110(11):abstract No. 2371
50. Roskos LK, Davis CG, Schwab GM. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res 2004;61:108-20 (Pubitemid 39043717)
51. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49(10):633-59
52. Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006;11(1-2):81-8 (Pubitemid 43227856)
53. Rosenberg AS, Worobec A. A risk-based approach to immunogenicity of therapeutic protein products, Part 1: considering consequences of theimmune response to a protein. BioPharm Int 2004;17:22-6. Available from: http://www. biopharminternational.com/biopharm/ article/articleDetail.jsp?id=134110 [[Last accessed 30 September 2011]
54. Humira® (adalimumab): US prescribing information. Abbott Laboratories, Chicago, IL, USA, 2011. Available from: http://www.rxabbott.com/ pdf/humira.pdf [Last accessed 31 May 2011] Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
55. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;54:3782-9 (Pubitemid 44955878)
56. Ducourau E, Mulleman D, Paintaud G, et al. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011;13:R105
57. Xu Z, Seitz K, Fasanmade A, et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008;48:681-95 (Pubitemid 351713154)
58. Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009;65:1211-28
59. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008;30:523-9
60. Guideline On Immunogenicity Assessment Of Biotechnology-Derived Therapeutic Proteins E, London,UK, 2007. Available from: http://www.ema. europa.eu/docs/en-GB/document-library/ Scientific-guideline/2009/09/ WC500003946.pdf [Last accessed 30 September 2011]
61. Newkirk MM, Novick J, Stevenson MM, Fournier MJ. Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice. Clin Exp Immunol 1996;106(2):259-64 (Pubitemid 26359891)
62. Huang L, Biolsi S, Bales KR, Kuchibhotla U. Impact of variable domain glycosylation on antibody clearance: an LC/MS characterization. Anal Biochem 2006;349(2):197-207 (Pubitemid 43184300)
63. Boswell CA, Deng R, Lin K, et al. In Vitro-In Vivo Correlations of Pharmacokinetics, Pharmacodynamics, and Metabolism for Antibody Therapeutics. In: Mrsny RJ, Daughtery A, editors. Proteins and Peptides: Pharmacokinetic, Pharmacodynamic, and Metabolic Outcomes. 1st edition. Informa Healthcare; 2009
64. Hutchins JT, Kull FC Jr, Bynum J, et al. Improved biodistribution, tumor targeting, and reduced immunogenicity in mice with a gamma 4 variant of Campath-1H. Proc Natl Acad Sci USA 1995;92(26):11980-4 (Pubitemid 26013994)
65. Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007;368(3):652-65 (Pubitemid 46527610)
66. Vugmeyster Y, Szklut P, Wensel D, et al. Complex pharmacokinetics of a humanized antibody against human amyloid beta peptide, Anti-Abeta Ab2, in nonclinical species. Pharm Res 2011;28(7):1696-706
67. Bumbaca D, Wong A, Drake E, et al. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs 2011;3:4
68. Boswell CA, Tesar DB, Mukhyala K, et al. Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 2010;21(12):2153-63
69. Khawli LA, Goswami S, Hutchinson R, et al. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. MAbs 2010;2(6):613-24
70. Putnam WS, Prabhu S, Zheng Y, et al. Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol 28(10):509-16
71. Igawa T, Tsunoda H, Tachibana T, et al. Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 2010;23(5):385-92
72. Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol 2007;47(9):1104-18
73. Simulect® (basiliximab): US prescribing information. Novartis Pharmaceuticals Corp, East Hanover, NJ, USA, 2005. Available from: http://www.pharma.us. novartis.com/product/pi/pdf/simulect.pdf [Last accessed 31 May 2011]
74. Bunescu A, Seideman P, Lenkei R, et al. Enhanced Fcgamma receptor I, alphaMbeta2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J Rheumatol 2004;31(12):2347-55 (Pubitemid 39603080)
75. Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies-mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel 2007;10(1):84-96 (Pubitemid 46438261)
76. Simponi® (golimumab): US prescribing information. Centocor Ortho Biotech Inc.,Horsham, PA, USA, 2010. Available from: https://www.simponi.com/ sites/ default/files/pdf/prescribing-information. pdf [Last accessed 1 June 2011]
77. Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010;48(5):297-308
78. Guidance for Industry: Pharmacokinetics in Patients with Impaired Renal Function - Study Design Data Analysis, and Impact on Dosing and Labeling. FDA, Washington, DC, USA, 2010. Available from: http:// www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation /Guidances/UCM204959.pdf [Last accessed 31 May 2011]
79. Guidance for Industry: Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design Data Analysis, and Impact on Dosing and Labeling. FDA, Washington, DC, USA, 2003. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation /Guidances/ucm072123.pdf [Last accessed 31 May 2011]
80. Remicade® (infliximab): US prescribing information. Centocor Ortho Biotech Inc. Horsham, PA, USA, 2011. Available from: http://www.remicade.com/ remicade/assets/hcp-ppi.pdf [Last accessed 1 June 2011]
81. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid Deng, Jin, Prabhu & Iyer Expert Opin. Drug Metab. Toxicol. (2012) 8(2) 157 tumors: a Children's Oncology Group Study. J Clin Oncol 2008;26(3):399-405 (Pubitemid 351171691)
82. Trippett TM, Herzog C, Whitlock JA, et al. Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: a study of the pediatric oncology experimental therapeutic investigators' consortium. J Clin Oncol 2009;27(30):5102-8
83. Malek A, Sager R, Kuhn P, et al. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 1996;36(5):248-55 (Pubitemid 26383975)
84. Hubbard JJ, Laurenzana EM, Williams DK, et al. The fate and function of therapeutic antiaddiction monoclonal antibodies across the reproductive cycle of rats. J Pharmacol Exp Ther 2011;336(2):414-22
85. Lievre A, Blons H, Laurent-Puig P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene 2010;29(21):3033-43
86. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104(9):2635-42 (Pubitemid 39434941)
87. Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64(13):4664-9 (Pubitemid 38856941)
88. Levy G. Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 1994;56:248-52 (Pubitemid 24323915)
89. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 2001;28(6):507-32 (Pubitemid 34289541)
90. Gibiansky L, Gibiansky E. Target-mediated drug disposition model for drugs that bind to more than one target. J Pharmacokinet Pharmacodyn 2010;37:323-46
91. Lammerts van Bueren JJ, Bleeker WK, Bogh HO, et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 2006;66(15):7630-8 (Pubitemid 44289220)
92. Ng CM, Bai S, Takimoto CH, et al. Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-alpha (5)beta (1) integrin monoclonal antibody (volociximab) in cancer patients. Cancer Chemother Pharmacol 2010;65(2):207-17
93. Hale G, Rebello P, Brettman LR, et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. Blood 2004;104(4):948-55 (Pubitemid 39043667)
94. Kuang B, King L, Wang HF. Therapeutic monoclonal antibody concentration monitoring: free or total? Bioanalysis 2:1125-40
95. Lee JW, Kelley M, King LE, et al. Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J 13:99-110
96. Ternant D, Mulleman D, Degenne D, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 2006;28:169-74 (Pubitemid 44314944)
97. Ceze N, Ternant D, Piller F, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of cetuximab. Ther Drug Monit 2009;31:597-601
98. Ternant D, Ceze N, Lecomte T, et al. An enzyme-linked immunosorbent assay to study bevacizumab pharmacokinetics. Ther Drug Monit 2010;32:647-52
99. Ezan E, Bitsch F. Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies. Bioanalysis 2009;1: 1375-88
100. Doucet J, Avrameas A. A novel method for quantitative measurement of a therapeutic monoclonal antibody in the presence of its target protein using enzymatic digestion. J Pharm Biomed Anal 2010;52(4):565-70
101. Dedrick RL. Animal scale-up. J Pharmacokinet Biopharm 1973;1(5):435-61
102. Jolling K, Perez Ruixo JJ, Hemeryck A, et al. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. Eur J Pharm Sci 2005;24(5):465-75 (Pubitemid 40387260)
103. Wang W, Prueksaritanont T. Prediction of human clearance of therapeutic proteins: simple allometric scaling method revisited. Biopharm Drug Dispos 2010;31(4):253-63
104. Ling J, Zhou H, Jiao Q, Davis HM. Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 2009;49(12): 1382-402
105. Deng R, Iyer S, Theil FP, et al. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: What have we learned? Mabs 2011;3(1):61-6
106. Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 2009;24(1):16-24
107. Duconge J, Castillo R, Crombet T, et al. Integrated pharmacokineticpharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. Eur J Pharm Sci 2004;21(2-3):261-70 (Pubitemid 38156163)
108. Kagan L, Abraham AK, Harrold JM, Mager DE. Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharm Res 2010;27(5):920-32
109. Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. FDA, Washington, DC, USA, 2005. Available from: http:// www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation /Guidances/ucm078932.pdf [Last accessed 31 May 2011]
110. Agoram BM. Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics. Br J Clin Pharmacol 2009;67(2):153-60
111. Lowe PJ, Hijazi Y, Luttringer O, et al. On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica 2007;37(10-11):1331-54 (Pubitemid 350035529)
112. Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products: EMA, London, UK, 2007. Available from: http://www.ema.europa.eu/docs/en-GB/ document-library/ Scientific-guideline/2009/ 09/WC500002988.pdf [Last accessed 31 May 2011]
113. Reigner BG, Blesch KS. Estimating the starting dose for entry into humans: principles and practice. Eur J Clin Pharmacol 2002;57(12):835-45 (Pubitemid 34185552)
114. Vugmeyster Y, Guay H, Szklut P, et al. In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus. Mabs 2010;2(3):335-46
115. Mager DE, Mascelli MA, Kleiman NS, et al. Simultaneous modeling of abciximab plasma concentrations and ex vivo pharmacodynamics in patients undergoing coronary angioplasty. J Pharmacol Exp Ther 2003;307(3):969-76 (Pubitemid 37494214)
116. Mould DR, Baumann A, Kuhlmann J, et al. Population pharmacokinetics- pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007;64(3):278-91 (Pubitemid 47283867)
117. Lu JF, Bruno R, Eppler S, et al. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol 2008;62(5):779-86
118. Ilaris® (canakinumab): US prescribing information. Novartis Pharmaceuticals Corp, East Hanover, NJ, USA, 2009. Available from: http://www.pharma.us. novartis.com/product/pi/pdf/ilaris.pdf [Last accessed 1 June 2011]
119. Removab®: EPAR - Product Information. EMA L, UK, 2011. Available from: http://www.ema.europa. eu/docs/en-GB/document-library/ EPAR-Product-Information/human/ 000972/WC500051809.pdf [Last accessed 12 July 2011]
120. Cimzia® (certolizumab pegol): US prescribing information. UCB Inc, Smyrna, GA, USA, 2008. Available from: http://www.cimzia.com/pdf/ Prescribing-Information.pdf [Last accessed 1 June 2011]
121. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18(4):904-14 (Pubitemid 30106623)
122. Zenapax- (daclizumab): US prescribing information. Hoffmann-La Roche Inc. Nutely, NJ, USA, 2005. Available from: http://www.gene.com/gene/products/ information/zenapax/pdf/pi.pdf [Last accessed 31 May 2011]
123. Marathe A, Peterson MC, Mager DE. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther 2008;326(2):555-62
124. Xgeva® (denosumab): US prescribing information. Amgen Inc, Thounsand Oaks, CA, USA, 2010. Available from: http://pi.amgen.com/united-states/xgeva/ xgeva-pi.pdf [Last accessed 31 May 2011]
125. Soliris® (eculizumab): US prescribing information. Alexion Pharmaceuticals Inc, Cheshire, CT, USA, 2009. Available from: http://www.soliris.net/Downloads/ pdf/soliris.pdf [Last accessed 31 May 2011]
126. Ng CM, Joshi A, Dedrick RL, et al. Pharmacokineticpharmacodynamic- efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res 2005;22(7):1088-100 (Pubitemid 41127066)
127. Mylotarg® (gemtuzumab ozogamicin for Injection): US prescribing information. Wyeth Pharmaceuticals Inc.,Philadelphia, PA, USA, 2010. Available from: http:// labeling.pfizer.com/showlabeling.aspx? id=119 [Last accessed 1 June 2011]
128. Zevalin® (ibritumomab tiuxetan): US prescribing information. Spectrum Pharmaceuticals Inc, Irvine, CA, USA, 2010. Available from: http://www. zevalin.com/v3/pdf/Zevalin-PI-Website. pdf [Last accessed 1 June 2011]
129. Orthoclone OKT®3 (muromonab- CD3): US prescribing information. Centocor Ortho Biotech Products L.P, Raritan, NJ, USA, 2011. Available from: http://www.janssenbiotech.com/assets/ OKT3-PI.pdf [Last accessed 12 July 2011]
130. Tysabri® (natalizumab): US prescribing information. Elan Pharmaceuticals Inc, South San Francisco, CA, USA and Biogen Idec Inc, Weston, MA, USA, 2011. Available from: http://www.tysabri. com/en-US/tysb/site/pdfs/ TYSABRI-pi. pdf [Last accessed 31 May 2011]
131. Arzerra® (ofatumumab): US prescribing information. GlaxoSmithKline Research Triangle Park, NC, USA, 2010. Available from: http://us.gsk.com/ products/assets/ us-arzerra.pdf [Last accessed 31 May 2011]
132. Synagis® (Palivizumab): US prescribing information. MedImmune LLC, Gaithersburg, MD, USA, 2011. Available from: http://www.medimmune.com/pdf/ products/synagis-pi.pdf [Last accessed 31 May 2011]
133. Lucentis® (ranibizumab injection): US prescribing information. Genentech Inc, South San Francisco, CA, USA, 2010. Available from: http://www.gene.com/ gene/products/information/pdf/lucentisprescribing. pdf [Last accessed 31 May 2011]
134. Rituxan® (rituximab): US prescribing information. Genentech Inc, South San Francisco, CA, USA and Biogen Idec Inc, Weston, MA, USA, 2011. Availablefrom: http://www.gene.com/gene/ products/information/pdf/ rituxanprescribing. pdf [Last accessed 31 May 2011]
135. Actemra® (tocilizumab): US prescribing information. Chugai Seiyaku Kabushiki Kaisha Corp.,a member of the Roche Group, Hoffmann-La Roche INC, Nutley, NJ, USA, 2011. Available from: http:// www.gene.com/gene/products/ information/actemra/pdf/pi.pdf [Last accessed 31 May 2011]
136. Bexxar® (Tositumomab and Iodine I 131 Tositumomab): US prescribing information. GlaxoSmithKline Research Triangle Park, NC, USA, 2005. Available from: http://us.gsk.com/products/ assets/us-bexxar.pdf [Last accessed 31 May 2011]
137. Bruno R,Washington CB, Lu JF, et al. Population pharmacokinetics of trastuzumab in patients with HER2 + metastatic breast cancer. Cancer Chemother Pharmacol 2005;56(4):361-9 (Pubitemid 41095399)
138. Stelara® (ustekinumab): US prescribing information. Centocor Ortho Biotech Inc. Horsham, PA, USA, 2010. Available from: http://www.stelarainfo.com/ pdf/ PrescribingInformation.pdf [Last accessed 1 June 2011]